According to the FMC, proceeds from the offering will be used to repay indebtedness, for acquisitions including the company’s recent acquisition of Euromedic’s dialysis service business and for general corporate purposes to support the renal products and services business.

The proposed offering will not be registered under the Securities Act of 1933.

The senior notes will be offered in the US to ‘qualified institutional buyers’ pursuant to the exemption from registration under Rule 144A of the Securities Act, and the offering will be made in an ‘offshore transaction’ pursuant to Regulation S under the Securities Act.